Maynard Um
-
-
-
-
-
-
-
Needham says this stock is 2026 winner as oral HAE drug gains early traction
-
-
-
-
-
-
-
Kalvista Pharma's (KALV) Ekterley One of The Harder Launches to Track - Citizens
-
-
-
-
-
-
-
Kalvista Pharmaceuticals Inc (KALV) PT Lowered to $36 at BofA Securities
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)
-
-
-
-
-
-
-
FDA approves KalVista's (KALV) oral HAE treatment EKTERLY
-
-
-
-
-
-
-
KalVista Pharmaceuticals (KALV) Announces FDA Will Not Meet PDUFA Goal Date for Sebetralstat
-
-
-
-
-
-
-
H.C. Wainwright Reiterates Buy Rating on Kalvista Pharmaceuticals Inc (KALV)
-
341,965 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

